Searching News Database: Glioblastoma multiforme
HSMN NewsFeed - 17 Nov 2021
Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
HSMN NewsFeed - 8 Oct 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 23 Jul 2020
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
HSMN NewsFeed - 3 Oct 2017
Oncorus(R), Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
Oncorus(R), Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 31 Oct 2016
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
HSMN NewsFeed - 26 Jul 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 12 Aug 2013
Teva Pharmaceutical And Perrigo Company Announce The U.S. Launch Of Generic Temozolomide
Teva Pharmaceutical And Perrigo Company Announce The U.S. Launch Of Generic Temozolomide
HSMN NewsFeed - 22 Jan 2013
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
HSMN NewsFeed - 13 Feb 2012
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
HSMN NewsFeed - 9 Jun 2011
Northwest Biotherapeutics Announces Change and Expansion of Management Team
Northwest Biotherapeutics Announces Change and Expansion of Management Team
HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
HSMN NewsFeed - 4 Jun 2009
ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial
ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial
HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
HSMN NewsFeed - 23 Jul 2008
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
HSMN NewsFeed - 21 May 2008
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
HSMN NewsFeed - 9 Apr 2008
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
HSMN NewsFeed - 14 Mar 2008
Genentech Provides Business Update at Annual Investment Community Meeting
Genentech Provides Business Update at Annual Investment Community Meeting
HSMN NewsFeed - 11 Mar 2008
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
HSMN NewsFeed - 22 Oct 2007
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
HSMN NewsFeed - 2 Aug 2007
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
HSMN NewsFeed - 9 Jul 2007
World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
HSMN NewsFeed - 26 Jun 2007
Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients
Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients
HSMN NewsFeed - 25 Jun 2007
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
HSMN NewsFeed - 4 Jun 2007
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
HSMN NewsFeed - 19 Apr 2007
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
HSMN NewsFeed - 19 Apr 2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
HSMN NewsFeed - 8 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
HSMN NewsFeed - 21 Feb 2007
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
HSMN NewsFeed - 16 Jan 2007
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
HSMN NewsFeed - 21 Dec 2006
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
HSMN NewsFeed - 20 Nov 2006
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
HSMN NewsFeed - 12 Oct 2006
Peregrine Receives Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
Peregrine Receives Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
HSMN NewsFeed - 20 Sep 2006
British Journal of Haematology Publishes Thrombosis Findings From ASCENT Trial
British Journal of Haematology Publishes Thrombosis Findings From ASCENT Trial
HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
Additional items found! 72
Members Archive contains
72 additional stories matching:
Glioblastoma multiforme
(Password required)
Glioblastoma multiforme
(Password required)